Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
FHIR APIs required by 2027
You may meet the clinical criteria if one of the following applies: Your starting BMI was 35 or higher
Favourable changes in cardiometabolic markers were also reported in the Phase 2 trial data, including reductions in: Systolic blood pressure Triglyceride levels Waist circumference (a proxy for visceral adiposity) However, these are surrogate markers and should not be interpreted as evidence of a reduction in major adverse cardiovascular events (MACE)
Adherence to the weekly injection schedule is essential for achieving optimal weight loss outcomes with tirzepatide
US$ 27.27
US$ 22.31
US$ 26.28
